Application of Neratinib in Breast Cancer Broadens

Rachel Narozniak, MA
Published: Wednesday, Apr 08, 2020
Adam M. Brufsky, MD, PhD, FACP, medical director of the MageeWomen's Cancer Program at the University of Pittsburgh Medical Center Hillman Cancer Center

Adam M. Brufsky, MD, PhD, FACP

The recent approval of neratinib (Nerlynx) in combination with capecitabine (Xeloda) for patients with late-stage, heavily pretreated HER2-positive breast cancer expanded the therapy’s established role in this disease setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication